サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：ファビピラビルの世界市場（2022年～2028年）
市場調査レポート
商品コード
1215699

ファビピラビルの世界市場（2022年～2028年）

Favipiravir Market 2022-2028
出版日: | 発行: Orion Market Research | ページ情報: 英文 | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
ファビピラビルの世界市場（2022年～2028年）
出版日: 2023年01月14日
発行: Orion Market Research
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のファビピラビルの市場規模は、予測期間中に4.1%のCAGRで大きく成長すると予測されています。

インフルエンザA/B、エボラ、COVID-19、その他の疾患を標的とした新薬の継続的な開発によって市場成長に効果的に貢献している主要企業の存在により、世界のファビピラビルの市場成長が促進されています。また、抗ウイルス薬ファビピラビルの製造・販売に関する規制当局の承認が高まっていることも、市場成長を後押しする要因となっています。

当レポートでは、世界のファビピラビル市場について調査分析し、市場概要、セグメント・地域別の市場分析、競合情勢、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 レポートの概要

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向

第3章 競合情勢

  • 主要企業分析
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の開発
  • 主要戦略分析

第4章 市場決定要因

  • 促進要因
  • 抑制要因
  • 機会

第5章 市場内訳

  • 世界のファビピラビル市場：用途別
    • インフルエンザA/B
    • エボラ
    • COVID-19
    • その他
  • 世界のファビピラビル市場：流通チャネル別
    • 病院・クリニック
    • ドラッグストア・薬局
    • オンライン

第6章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • その他の地域
    • ラテンアメリカ
    • 中東・アフリカ

第7章 企業プロファイル

  • Beacon Pharmaceuticals. Ltd.
  • ChemRar Group
  • Cipla. Ltd.
  • Dr. Reddy's Laboratories. Ltd.
  • Fujifilm Toyoma Chemicals Co. Ltd.
  • Glenmark Pharmaceuticals. Ltd.
  • Lupin Healthcare. Ltd.
  • R-Pharma
  • Sun Pharmaceutical Industries. Ltd.
  • Zhejiang Hisun Pharmaceutical Co. Ltd
図表

LIST OF TABLES

  • 1. GLOBAL FAVIPIRAVIR MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 2. GLOBAL FAVIPIRAVIR IN INFLUENZA A&B MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL FAVIPIRAVIR IN EBOLA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL FAVIPIRAVIR IN COVID-19 MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 5. GLOBAL FAVIPIRAVIR OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBAL FAVIPIRAVIR MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
  • 7. GLOBAL FAVIPIRAVIR IN HOSPITALS & CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 8. GLOBAL FAVIPIRAVIR IN DRUG STORES/PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 9. GLOBAL FAVIPIRAVIR IN ONLINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. GLOBAL FAVIPIRAVIR MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 11. NORTH AMERICAN FAVIPIRAVIR MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 12. NORTH AMERICAN FAVIPIRAVIR MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 13. NORTH AMERICAN FAVIPIRAVIR MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
  • 14. EUROPEAN FAVIPIRAVIR MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 15. EUROPEAN FAVIPIRAVIR MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 16. EUROPEAN FAVIPIRAVIR MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
  • 17. ASIA-PACIFIC FAVIPIRAVIR MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 18. ASIA-PACIFIC FAVIPIRAVIR MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 19. ASIA-PACIFIC FAVIPIRAVIR MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)
  • 20. REST OF THE WORLD FAVIPIRAVIR MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 21. REST OF THE WORLD FAVIPIRAVIR MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 22. REST OF THE WORLD FAVIPIRAVIR MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL FAVIPIRAVIR MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
  • 2. GLOBAL FAVIPIRAVIR MARKET SHARE BY DISTRIBUTION CHANNEL, 2021 VS 2028 (%)
  • 3. GLOBAL FAVIPIRAVIR MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 4. GLOBAL FAVIPIRAVIR IN INFLUENZA A&B MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 5. GLOBAL FAVIPIRAVIR IN EBOLA MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 6. GLOBAL FAVIPIRAVIR IN COVID-19 MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 7. GLOBAL FAVIPIRAVIR OTHER APPLICATIONS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 8. GLOBAL FAVIPIRAVIR IN HOSPITALS & CLINICS MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 9. GLOBAL FAVIPIRAVIR IN DRUG STORES/PHARMACIES MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 10. GLOBAL FAVIPIRAVIR IN ONLINE MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 11. US FAVIPIRAVIR MARKET SIZE, 2021-2028 ($ MILLION)
  • 12. CANADA FAVIPIRAVIR MARKET SIZE, 2021-2028 ($ MILLION)
  • 13. UK FAVIPIRAVIR MARKET SIZE, 2021-2028 ($ MILLION)
  • 14. FRANCE FAVIPIRAVIR MARKET SIZE, 2021-2028 ($ MILLION)
  • 15. GERMANY FAVIPIRAVIR MARKET SIZE, 2021-2028 ($ MILLION)
  • 16. ITALY FAVIPIRAVIR MARKET SIZE, 2021-2028 ($ MILLION)
  • 17. SPAIN FAVIPIRAVIR MARKET SIZE, 2021-2028 ($ MILLION)
  • 18. REST OF EUROPE FAVIPIRAVIR MARKET SIZE, 2021-2028 ($ MILLION)
  • 19. INDIA FAVIPIRAVIR MARKET SIZE, 2021-2028 ($ MILLION)
  • 20. CHINA FAVIPIRAVIR MARKET SIZE, 2021-2028 ($ MILLION)
  • 21. JAPAN FAVIPIRAVIR MARKET SIZE, 2021-2028 ($ MILLION)
  • 22. SOUTH KOREA FAVIPIRAVIR MARKET SIZE, 2021-2028 ($ MILLION)
  • 23. REST OF ASIA-PACIFIC FAVIPIRAVIR MARKET SIZE, 2021-2028 ($ MILLION)
  • 24. REST OF THE WORLD FAVIPIRAVIR MARKET SIZE, 2021-2028 ($ MILLION)
目次
Product Code: OMR2026755

Title:Global Favipiravir Market Size, Share and Trends Analysis Report, By Application (Influenza A&B, Ebola, COVID-19, and Others), By Distribution Channel (Hospitals & Clinics, Drug Stores/Pharmacies, and Online) Forecast Period (2022-2028).

The global favipiravir market is anticipated to grow at a substantial CAGR of 4.1% during the forecast period. The global favipiravir market growth is driven by the presence of major players that are contributing effectively to the growth of the market by continuous development of new drugs targeting Influenza A&B, Ebola, COVID-19, and other diseases. The rising regulatory approvals for the manufacturing and marketing of antiviral drug favipiravir is also the factor driving the market growth. For instance, in July 2020, Cipla Ltd. Received approval for the launch of the anti-viral drug favipiravir in India under the brand name 'Ciplenza' for the treatment of COVID-19 patients. The drug has been jointly developed by Cipla and CSIR-Indian Institute of Chemical Technology (IICT). Similarly, in June 2020, India-based Glenmark Pharmaceuticals got approval for the manufacturing and marketing of favipiravir under the brand name FabiFlu to treat mild to moderate COVID-19.

The global favipiravir market is segmented based on application and distribution channels. Based on application, the market is sub-segmented into Influenza A&B, Ebola, COVID-19, and others. Among these, the use of favipiravir in COVID-19 disease treatment is expected to increase more during the forecast period, thereby driving segment growth. Ongoing R&D and clinical trials for the efficacy of favipiravir in the treatment of COVID-19 will drive segment growth. Similarly, based on distribution channels, the market is sub-segmented into hospitals & clinics, drug stores/pharmacies, and online.

Geographically, the favipiravir market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. Europe is projected to witness notable growth in the market during the forecast period. The increasing prevalence of Ebola in Europe is increasing the demand for favipiravir. The increased approval of the favipiravir drug has positively affected regional market growth. In November 2019, the European Commission granted marketing authorization to Merck's vaccine, known as Ervebo for Ebola. The vaccine was designed at Canada's National Microbiology Laboratory with funding from the U.S. government's Biomedical Advanced Research and Development Authority, for the protection against the Zaire species of Ebola.

The major market players in the global favipiravir market include Fujifilm Toyoma Chemicals Co. Ltd., Cipla Ltd., Sun Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd., and Dr. Reddy's Laboratories Ltd., among others. The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market. For instance, in July 2020, Dr. Reddy's Laboratories Ltd. Collaborated with Fujifilm to launch the innovator brand of favipiravir "Avigan" in India. The partnership accelerated the company's development, manufacture, and sales of Avigan tablets.

Research Methodology

The market study of the global favipiravir market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of the market size, and intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global Favipiravir Market Research and Analysis by Application
  • Global Favipiravir Market Research and Analysis by Distribution Channel

The Report Covers:

  • Comprehensive research methodology of the global favipiravir market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global favipiravir market.
  • Insights about market determinants that are stimulating the global favipiravir market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Favipiravir Industry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Favipiravir Market by Application
    • 5.1.1. Influenza A&B
    • 5.1.2. Ebola
    • 5.1.3. COVID-19
    • 5.1.4. Others
  • 5.2. Global Favipiravir Market by Distribution Channel
    • 5.2.1. Hospitals & Clinics
    • 5.2.2. Drug Stores/Pharmacies
    • 5.2.3. Online

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World
    • 6.4.1. Latin America
    • 6.4.2. Middle East & Africa

7. Company Profiles

  • 7.1. Beacon Pharmaceuticals. Ltd.
  • 7.2. ChemRar Group
  • 7.3. Cipla. Ltd.
  • 7.4. Dr. Reddy's Laboratories. Ltd.
  • 7.5. Fujifilm Toyoma Chemicals Co. Ltd.
  • 7.6. Glenmark Pharmaceuticals. Ltd.
  • 7.7. Lupin Healthcare. Ltd.
  • 7.8. R-Pharma
  • 7.9. Sun Pharmaceutical Industries. Ltd.
  • 7.10. Zhejiang Hisun Pharmaceutical Co. Ltd